Text and Data Mining valid from 2019-06-12
Received: 9 March 2019
Accepted: 31 May 2019
First Online: 12 June 2019
Compliance with ethical standards
: We wish to confirm that there are no known conflicts of interest associated with this publication. A Iravani, GA Turgeon, T Akhurst, JW Callahan, M Bressel, SJ Everitt and MP Mac Manus have no disclosure. Through his institution, DL Ball has an advisory role for Pfizer Australia. RJ Hicks has ownership interest in Telix Radiopharmaceuticals. Through his institution, S Siva has an advisory role for Astellas Pharmaceuticals and Janssen Pharmaceuticals and receives research funding from Varian Medical Systems and Merck Sharp & Dohme Pharmaceuticals. S Siva received speakers’ bureau, travel/accommodations/expenses from Bristol-Myers Squibb Pharmaceuticals as well as travel/accommodation/expenses from Astellas Pharmaceuticals.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.The registration number for the prospective studies were as follows, PET-planning study: Peter Mac protocol 03/55; the Superscript removedF-FLT/Superscript removedF-FDG study: Australian Clinical Trials Registry no. ACTRN12611001283965; and the Superscript removedGa-ventilation/perfusion PET study: universal trial number U1111-1138-4421. The Peter MacCallum Cancer Clinical Research and Ethics Committee approved this retrospective study and waived the requirement to obtain informed consent (approval number: PMCC 17/43R). All patients had previously provided written informed consent to undergo their respective prospective studies.